RT-111
Inflammatory Diseases (Ustekinumab Biosimilar)
Phase 1Active
Key Facts
Indication
Inflammatory Diseases (Ustekinumab Biosimilar)
Phase
Phase 1
Status
Active
Company
About Rani Therapeutics
Rani Therapeutics' mission is to replace injectable biologics with convenient oral pills using its innovative RaniPill™ technology, which mechanically delivers drugs through the intestinal wall. The company has achieved key clinical milestones, demonstrating safety, tolerability, and bioavailability comparable to subcutaneous injections for its lead osteoporosis and ustekinumab biosimilar programs. Its strategy is to validate the platform through proprietary programs and subsequently pursue high-value partnerships with large biopharma companies to apply the technology to a broad range of biologic assets.
View full company profile